Stock Price Quote

ADVANCED ENZYME TECHNOLOGIES LTD.

NSE : ADVENZYMESBSE : 540025ISIN CODE : INE837H01020Industry : Pharmaceuticals & DrugsHouse : Private
BSE339.75-4.5 (-1.31 %)
PREV CLOSE ( ) 344.25
OPEN PRICE ( ) 352.05
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 3775
TODAY'S LOW / HIGH ( )338.90 352.05
52 WK LOW / HIGH ( )332 571.15
NSE339.85-4.1 (-1.19 %)
PREV CLOSE( ) 343.95
OPEN PRICE ( ) 342.55
BID PRICE (QTY) 339.85 (482)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 67591
TODAY'S LOW / HIGH( ) 339.15 346.95
52 WK LOW / HIGH ( )331.3 571
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 15-03 1989
Management Info
Vasant Rathi - Chairman - Managing Director
Registered Office

Address Sun- Magnetica, A Wing,5th Floor, Near L I C Service Road,Louiswadi,
Thane,
Maharashtra-400604

Phone 022 41703200

Email info@advancedenzymes.com

Website www.advancedenzymes.com

Registrars Details
MUFG Intime India Pvt Ltd.
C 101, 247 Park,LBS Marg,Vikhroli (West),Mumbai
Listing : BSE, NSE

NEWS

19Dec Advanced Enzyme Technologies completes
Advanced Enzyme Technologies has completed the further investment in Adv..
16Dec Advanced Enzyme Technologies informs a
Advanced Enzyme Technologies has informed that pursuant to the Securitie..
05Dec Advanced Enzyme Technologies’ arm gets
Advanced Enzyme Technologies’ wholly owned subsidiary -- Advanced Enzyme..
05Dec Advanced Enzyme Technologies informs a
Advanced Enzyme Technologies has informed that the Board of Directors of..
11Nov Advanced Enzyme Technologies informs a
Advanced Enzyme Technologies has informed that it enclosed copy of the n..

Financials

in Millions
QTR Sep 24 ANNUAL 24
Net Profit91.26000000000011081.23
Gross Profit 123.21 1339.92
Operating Profit 151.811639.95
Net Sales 773.783654.69

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Abbott India (BSE)
peergroup  27951.80 (2.35%)
M.Cap ( in Cr)59395.62
Astrazeneca Pharma I (BSE)
peergroup  6913.95 (1.73%)
M.Cap ( in Cr)17284.88
Bajaj Healthcare (BSE)
peergroup  670.80 (19.38%)
M.Cap ( in Cr)2118.60
Alkem Laboratories (BSE)
peergroup  5251.20 (1.33%)
M.Cap ( in Cr)62785.97
Alembic Pharma (BSE)
peergroup  1053.40 (5.26%)
M.Cap ( in Cr)20705.96

Shareholding Pattern

MUTUAL FUNDS/UTI 5.57%
PROMOTERS 42.93%
NON-INSTITUTION 36.32%
FI/BANKS/INSURANCE 0%
GOVERNMENT 0%
FII 0%

About Advanced Enzyme Technologies Ltd.

Advanced Enzyme Technologies Ltd. was incorporated in the year 1989. Its today's share price is 339.75. Its current market capitalisation stands at Rs 3801.15 Cr. In the latest quarter, company has reported Gross Sales of Rs. 3662.79 Cr and Total Income of Rs.4244.08 Cr. The company's management includes Vinodkumar Hiralal Jajoo, Mukund M Kabra, Vandana Tilak, Sunny Sharma, Rasika Rathi, Nitin Deshmukh, Rajshree Patel, Pramod Kasat, Vasant Rathi, Sanjay Basantani.

It is listed on the BSE with a BSE Code of 540025 , NSE with an NSE Symbol of ADVENZYMES and ISIN of INE837H01020. It's Registered office is at Sun- Magnetica, A Wing,5th Floor, Near L I C Service Road,LouiswadiThane-400604, Maharashtra. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are BSR & Co LLP, MM Nissim & Co, MSKA & Associates, Walker Chandiok & Co LLP, Walker, Chandiok & Co

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.